Processa Pharmaceuticals, Inc. (PCSA)

Director David Young bought 1,545 Processa shares at $2.97, lifting direct holdings to 15,345 shares, while the filing also corrects a prior Form 4.

Processa Pharmaceuticals CFO Russell Skibsted bought 1,984 shares at $2.97, lifting his holdings to 8,466 shares, and corrected an earlier April 30 trade for a small pricing and 16-share error.

George K. Ng, Chief Executive Officer of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), acquired shares of the company’s common stock on April 15, 2026. The transaction involved the purchase of 1,843 shares at a price of $2.97 per share, totaling $5,473. The stock currently trades at $2.61, ...

Sian Bigora, Chief Development Officer at Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), recently increased her holdings in the company through a stock purchase. According to an amended Form 4 filing with the Securities and Exchange Commission, Ms.

Processa Pharmaceuticals CFO Russell Skibsted bought 2,190 Common Stock shares at $2.69, raising his direct holdings to 6,498 shares in an open-market transaction.